Abstract: The invention provides a preparation method of the matrix material for the gas diffusion layer of a fuel cell. The matrix material is obtained on the polyurethane sponge through the following process: conductively treating, electroplating, dissolving nickel by electrolysis, heat-treating, tungsten-nickel alloy electroplating, heat-treating, rolling. The mass content of the metal nickel of the matrix material is 88˜92%, and the mass content of the metal tungsten is 8˜12%. The material prepared by the invention has a high specific surface area, excellent thermal conductivity and gas permeability performance, excellent electrical corrosion resistance and oxidation resistance. After being prepared as the gas diffusion layer, as the diffusion layer and fuel cell electrode are closely connected, the material can effectively resist the electrochemical corrosion of the diffusion layer caused by the electrochemical reaction and is suitable for the matrix material of the gas diffusion layer.

Abstract: The invention provides a matrix material for the gas diffusion layer of the polymer electrolyte membrane fuel cell, which is composed of three-dimensional porous and strip-shaped hexagonal chambers connected to each other, wherein the six-sided ribs are composed of two metal layers, the inside is metal nickel, and the outside is tungsten-nickel alloy. The total mass of metal per square meter of the material is: 1500˜3000 grams, the mass content of metal nickel in the material is 88˜92%, the mass content of metal tungsten is 8˜12%, and the rest are impurities; the thickness of the matrix material is 0.1˜0.2 mm, specific surface area is (1˜2)×105 m2/m3; longitudinal air permeability ?2000 m/mm/(cm2hmmAq), longitudinal thermal conductivity ?1.7W/(m·k), transverse thermal conductivity ?21W/(m·K). The porous nickel-tungsten metal material of the invention, as the matrix material of the gas diffusion layer, has the advantages of lower electrical resistance and higher strength compared with carbon paper.

Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.

Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.

Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.